JP2011508775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011508775A5 JP2011508775A5 JP2010541450A JP2010541450A JP2011508775A5 JP 2011508775 A5 JP2011508775 A5 JP 2011508775A5 JP 2010541450 A JP2010541450 A JP 2010541450A JP 2010541450 A JP2010541450 A JP 2010541450A JP 2011508775 A5 JP2011508775 A5 JP 2011508775A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- hypertension
- responsive state
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 206010020772 Hypertension Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 208000019553 vascular disease Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000011252 Phenylketonuria Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 claims 2
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 claims 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000014249 Classic phenylketonuria Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000014252 Mild phenylketonuria Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1873508P | 2008-01-03 | 2008-01-03 | |
| US1975308P | 2008-01-08 | 2008-01-08 | |
| PCT/US2008/069319 WO2009088530A1 (en) | 2008-01-03 | 2008-07-07 | Pterin analog for treating bh4 responsive condition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011508775A JP2011508775A (ja) | 2011-03-17 |
| JP2011508775A5 true JP2011508775A5 (enExample) | 2011-08-25 |
Family
ID=39765023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541450A Ceased JP2011508775A (ja) | 2008-01-03 | 2008-07-07 | Ｂｈ４応答性状態を治療するためのプテリン類似体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7601717B2 (enExample) |
| EP (1) | EP2224927B1 (enExample) |
| JP (1) | JP2011508775A (enExample) |
| CN (1) | CN101969953B (enExample) |
| AU (1) | AU2008347005B2 (enExample) |
| BR (1) | BRPI0821970A2 (enExample) |
| CA (1) | CA2711160A1 (enExample) |
| ES (1) | ES2524026T3 (enExample) |
| MX (1) | MX2010006025A (enExample) |
| RU (1) | RU2470642C2 (enExample) |
| WO (1) | WO2009088530A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2675134A1 (en) * | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Pterin analogs |
| JP5066756B2 (ja) * | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| US20130338176A1 (en) * | 2010-10-29 | 2013-12-19 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating hyperlipidemia or atherosclerosis |
| WO2013055954A1 (en) * | 2011-10-11 | 2013-04-18 | The Regents Of The University Of California | Biomarker for abdominal aortic aneurysm |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| DK2919780T3 (en) | 2012-11-14 | 2018-11-26 | Bial Portela & Ca Sa | 1,3-Dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| AU2015374379B2 (en) * | 2014-12-30 | 2018-10-04 | Dow Agrosciences Llc | Picolinamides as fungicides |
| PH12018501923B1 (en) | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| KR20190138683A (ko) * | 2017-04-21 | 2019-12-13 | 스티븐 호프만 | 망막병증을 치료하기 위한 조성물 및 방법 |
| WO2019067782A1 (en) * | 2017-09-28 | 2019-04-04 | University Of Massachusetts | COMBINED TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
| WO2019175332A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| JP7553906B2 (ja) * | 2018-11-01 | 2024-09-19 | 宏 一瀬 | Ｓｐｒをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物 |
| CN112394178B (zh) * | 2020-11-16 | 2022-08-05 | 首都医科大学附属北京朝阳医院 | 莫西沙星相关肝损伤的生物标志物、试剂盒及应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2601215A (en) | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
| US3505329A (en) | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
| JPS5883691A (ja) | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法 |
| JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| CH651755A5 (en) | 1982-03-03 | 1985-10-15 | Kanegafuchi Chemical Ind | Use of pterin derivatives |
| JPS5976086A (ja) | 1982-09-20 | 1984-04-28 | ザ ウエルカム フアウンデ−シヨン リミテツド | プテリジン化合物 |
| GB8318833D0 (en) | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
| JPS59112987A (ja) * | 1982-12-20 | 1984-06-29 | Kanegafuchi Chem Ind Co Ltd | １′，２′―ジアシル―（６ｒ，ｓ）―５，６，７，８―テトラヒドロ―ｌ―ビオプテリンおよびその製法 |
| US5196533A (en) | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
| US4587340A (en) | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
| JPS60178887A (ja) | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法 |
| JPS60199889A (ja) | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法 |
| US4550109A (en) * | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
| JPS617287A (ja) | 1984-06-21 | 1986-01-13 | Kanegafuchi Chem Ind Co Ltd | ５‐デオキシ‐ｌ‐アラビノースの製造法 |
| US4713454A (en) | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
| JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| DE3520896A1 (de) * | 1985-06-11 | 1986-12-11 | Wolfgang Prof. Dr.Dr.h.c. 7750 Konstanz Pfleiderer | Neue pterin-derivate und diese enthaltende arzneimittel |
| JPS61293983A (ja) | 1985-06-22 | 1986-12-24 | Kanegafuchi Chem Ind Co Ltd | ５ｎ−アシルテトラヒドロプテリン化合物 |
| GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
| US4937342A (en) | 1987-11-30 | 1990-06-26 | Kabushiki Kaisha Vitamin Kenkyusyo | Intermediates for synthesizing BH4 and its derivatives |
| JP2575781B2 (ja) | 1988-02-29 | 1997-01-29 | 日清製粉株式会社 | ２，３−ジアシルオキシ−４−ヒドロキシ−トペンタナールおよびその製造方法 |
| US5043339A (en) | 1988-12-19 | 1991-08-27 | Burroughs Wellcome Co. | Antiviral compounds |
| US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
| DE4308739C1 (de) | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
| DE4418097A1 (de) | 1994-05-24 | 1995-11-30 | Cassella Ag | Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase |
| US5753656A (en) * | 1994-08-05 | 1998-05-19 | Suntory Limited | Method for treating spinocerebellar degeneration |
| DE69733308D1 (de) | 1996-07-31 | 2005-06-23 | Cmic Co | Aktivsauerstoffaufnehmer enthaltende pterinderivate |
| DE69725721T3 (de) * | 1996-08-30 | 2007-10-31 | Daiichi Asubio Pharma Co., Ltd. | Vorbeugende oder heilende mittel für krankheiten, die durch mangel an stickoxid-synthase (nos) ausgelöst sind |
| JP4306825B2 (ja) | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
| DE19944767A1 (de) | 1999-09-17 | 2001-03-29 | Vasopharm Biotech Gmbh & Co Kg | N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2420374A1 (en) | 2000-08-31 | 2003-02-24 | Suntory Limited | Process for production of biopterin compound |
| US20030078231A1 (en) | 2001-06-22 | 2003-04-24 | Wilburn Michael D. | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties |
| DE10260263A1 (de) * | 2002-12-20 | 2004-07-15 | Biocrates Life Sciences Gmbh | Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen |
| WO2005037286A1 (en) * | 2003-03-25 | 2005-04-28 | Vasopharm Biotech Gmbh | Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia |
| US20070167353A1 (en) | 2003-10-24 | 2007-07-19 | John Hilfinger | Prodrug composition |
| US20050137141A1 (en) | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| PT3138566T (pt) | 2003-11-17 | 2022-02-02 | Biomarin Pharm Inc | Tratamento de fenilcetonúria com bh4 |
| US7067659B2 (en) | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
| JP2008504295A (ja) | 2004-06-25 | 2008-02-14 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 注意欠陥多動性障害及び高フェニルアラニン血症の治療のための方法及び組成物 |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| US20100130500A1 (en) | 2004-12-08 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| US20060194800A1 (en) | 2005-01-07 | 2006-08-31 | University Of Strathclyde | Pteridine derivatives as nitric oxide synthase activators |
| US20060194808A1 (en) * | 2005-01-14 | 2006-08-31 | Chronorx Llc, An Alaska Limited Liability Company | Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate |
| WO2007067570A1 (en) | 2005-12-05 | 2007-06-14 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of disease |
| CA2675134A1 (en) | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Pterin analogs |
-
2008
- 2008-07-07 AU AU2008347005A patent/AU2008347005B2/en not_active Ceased
- 2008-07-07 RU RU2010132278/04A patent/RU2470642C2/ru active
- 2008-07-07 EP EP08781435.6A patent/EP2224927B1/en not_active Not-in-force
- 2008-07-07 CN CN2008801242617A patent/CN101969953B/zh not_active Expired - Fee Related
- 2008-07-07 JP JP2010541450A patent/JP2011508775A/ja not_active Ceased
- 2008-07-07 WO PCT/US2008/069319 patent/WO2009088530A1/en not_active Ceased
- 2008-07-07 CA CA2711160A patent/CA2711160A1/en not_active Abandoned
- 2008-07-07 MX MX2010006025A patent/MX2010006025A/es active IP Right Grant
- 2008-07-07 BR BRPI0821970-2A patent/BRPI0821970A2/pt not_active Application Discontinuation
- 2008-07-07 ES ES08781435.6T patent/ES2524026T3/es active Active
- 2008-10-29 US US12/260,855 patent/US7601717B2/en not_active Expired - Fee Related
-
2009
- 2009-10-12 US US12/577,680 patent/US8324210B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010132278A (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| HRP20100725T1 (hr) | Derivati ksantina kao selektivni agonisti hm74a | |
| JP2021063119A (ja) | 噴霧乾燥製剤 | |
| EA200701101A1 (ru) | Производные 3-фенилпиразола в качестве модуляторов 5-htсеротонинового рецептора, полезные для лечения расстройств, связанных с этим рецептором | |
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| MX2009004467A (es) | Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk). | |
| JO2954B1 (en) | Pirazol derivatives used as serotonin 5-Ht2a receptor controllers useful in the treatment of disorders related to these receptors | |
| JP2014526441A5 (enExample) | ||
| CN102050888B (zh) | 一种依诺肝素钠的制备方法 | |
| JP2010530385A (ja) | 置換オキサゾリジノン類およびそれらの使用 | |
| EA200701361A1 (ru) | Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ | |
| JP6782855B2 (ja) | 選択性ブルトン型チロシンキナーゼ阻害剤及びその使用 | |
| WO2008050101A3 (en) | Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk | |
| WO2008054748A3 (en) | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| WO2018169742A1 (en) | Apoptosis signal-regulating kinase inhibtor | |
| JP2009545310A5 (enExample) | ||
| KR20220098757A (ko) | Bet 브로모도메인 억제제 및 나트륨 의존 글루코스 수송 2 억제제와 병용하여 주요 부정적 심혈관 사건 (mace)을 치료 및/또는 예방하는 방법 | |
| JP5352461B2 (ja) | アミノアシルプロドラッグ誘導体および血栓塞栓性障害の処置用の医薬 | |
| JP2021520394A5 (enExample) | ||
| CN102464652B (zh) | 咪唑衍生物、制备方法及用途 | |
| JP2011504736A5 (enExample) | ||
| Mammadova-Bach et al. | Immuno-thrombotic effects of platelet serotonin | |
| JP4464560B2 (ja) | 置換イソインドロンおよび医薬におけるサイクリックｇｍｐ調節剤としてのそれらの使用 | |
| CN116549433A (zh) | 木犀草素在制备血小板糖蛋白vi抑制剂中的应用 | |
| CN106831740B (zh) | 一种恩曲他滨中间体的制备工艺 |